112th ASCPT Annual Meeting

Posted:
9
February 2011

Come see us at booth number 528 for this year�s 112th ASCPT Annual Meeting, the premier event for clinical pharmacologists, taking place 2nd to 5th March 2011 in Dallas, Texas.What�s on offer?

  • Over 30 educational sessions and 300 poster presentations
  • Lectures from top professionals in the industry
  • Networking opportunities with clinical pharmacologists from  around the world

Dr J rg fT ubel, medical practitioner and CEO of Richmond Pharmacology, will be presenting two of Richmond Pharmacology s latest publications centred on the following key areas of discussion:

  • COMPARISON OF DIGITAL 12-LEAD ECG AND DIGITAL 12-LEAD HOLTER ECG RECORDINGS IN HEALTHY MALE SUBJECTS - Poster Number: PI-08, scheduled on 3/3/2011 from 8:00 AM
  • FOOD EFFECT ON QTC INTERVAL IN THOROUGH QT STUDIES CONDUCTED IN HEALTHY SUBJECTS - Poster Number: LBII-1, scheduled on 4/3/2011 from 8.00 AM to 9.30 AM

For further details, please refer to the online brochure for program highlights, a schedule of events, student and trainee events.We look forward to seeing you in Dallas!

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more